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 As it remains, cardiovascular disease (CVD) has been the leading cause of mortality 
across the globe accounting for as many as 17.9 million deaths per year and projected to 
increase to more than 23.6 million deaths by 2030.1 Of the CVD related deaths, the majority are 
due to acute myocardial infarctions (AMI) and cerebral vascular accidents (CVA) and are 
associated with modifiable risk factors such as obesity, dyslipidemia, hypertension, and 
diabetes.2 Lifestyle modifications for decreasing these risk factors have been actively 
emphasized in healthcare, but do not eliminate the risks entirely. In addition to diet, exercise, 
and smoking cessation, other modifiable risk reduction should be explored. One area of 
particular interest pertains to the gut microbiome. As the understanding of gut health expands, 
the connections between microbiome disruptions and disease processes, such as cardiovascular 
disease, have suggested microbiota may affect health risks. Advances in the ability to analyze 
the plethora microbiota in the human gut have made it possible to both identify and quantify 
specific innate bacteria. This ability has provided a better understanding of the roles, functions, 
and potential alterations of the gut microbiome that are seen in various disease processes.  
 Analyzing alterations of the gut microbiome, if any, in persons with CVD or its risk 
factors is a key first step. Then, identifying any associations between an altered gut microbiome 
and dietary ASCVD risk factors, specifically obesity and dyslipidemia, may enhance not only the 
understanding of the underlying pathophysiology, but also the prospects of finding means to 






 The gut microbiome is comprised of trillions of bacteria, grouped by six major phyla:  
Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Fusobacteria, and Verrucomicrobia 
phylae, which are under the constant influence of external factors, such as dietary intake, 
antibiotic use, and infection.3 The gut microbiome is responsible for a number of biological 
functions through various mechanisms including saccharolytic metabolism, activation of 
immune responses through Toll-like receptors (TLRs), and trimethylamine N-oxide (TMAO) 
production. By way of saccharolytic metabolism, comes essential sources of energy from the 
byproducts of short-chain fatty acids (SCFAs) including acetate, butyrate, and propionate. 4  
 The gut microbiome serves to mitigate immune responses through TLR ligands by 
sensing bacterial components which in turn generate proinflammatory cytokine cascades. A 
study by Miura et al found that chronic low-inflammatory states such as obesity are mediated 
by increased activation of TLR signaling. In obese mice, alterations in gut microbiota, are 
evidenced by an increased number of bacteria from the Firmicutes phylum in the gut 
microbiota and a decreased number of bacteria from the Bacteroidetes phylum, in addition to 
elevations in specific TLRs .5 While immune response activation is essential for the host to ward 
off offending pathogenic microbes, constant activation can promote a perpetual state of 
inflammation leading to organ and tissue destruction. 
 The gut microbiome might increase CVD risk through its generation of TMAO, an 
atherogenic metabolite. Numerous animal and human studies have shown that the gut 
microbiota affect metabolism of substrates from phosphatidylcholine which is found in animal 
proteins. The breakdown of phosphatidylcholine is mediated by gut microbes and produces 
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TMAO. High levels of plasma TMAO were seen in one study in mice that were administered 
radiolabeled phosphatidylcholine and were followed by greater arterial plaque development. 
Hence, TMAO levels may be an indicator of ASCVD risk.  
 Extrapolating this hypothesis from animal studies, human subjects were examined for a 
possible relationship between TMAO plasma levels and ASCVD. In two separate studies the 
levels of TMAO were measured in large cohorts of patients who were undergoing cardiac 
evaluations. Those with the most significant risk of having a major cardiac event had the highest 
levels of TMAO. Thus, in humans, high TMAO are associated with increased ASCVD risk 6.  
 
Discussion 
  Many of the risk factors for ASCVD, like obesity and lipid dysfunction, have overlapping 
pathophysiologies in which metabolic dysregulation has a major role. This overlap makes 
identifying the effects of isolated microbes and their mechanisms for dysfunction difficult to 
separate from other possible effects associated with other CVD risk factors, such as obesity and 
dyslipidemia. Furthermore, much of the current evidence evaluating the gut microbiome, 
metabolic dysregulation, and influence on ASCVD and risk factor disease states are through 
case-control and cross-sectional analysis in human subjects. Randomized, controlled trials with 
manipulation of the gut microbiome to assess its effects on ASCVD outcomes are not feasible at 
this time, although evaluating the effects of gut microbiota on surrogate endpoints of ASCVD 
(ASCVD modifiable risk factors, TMAO levels, and other markers) is certainly achievable.  Thus, 
research specifically examining TMAO levels, obesity, and dyslipidemia, other risk markers in 
relation to the composition of the gut microbiome may provide new knowledge of the 
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pathophysiology of ASCVD as well as suggest means of decreasing ASCVD risks by altering the 
gut microbiome. 
 
Dietary Influences and TMAO Levels 
 Dietary trends are constantly changing; albeit they are not always supported by 
scientific evidence. Moreover, such diets are recommended by media outlets, personal fitness 
coaches, or family, who may not have expertise in nutrition. Although weight loss fads and diets 
move in and out of popularity, omnivorous and vegetarian diets remain constant. The ongoing 
CARNIVAL non-blinded, randomized, interventional clinical trial is currently comparing these 
two diets by examining the effect of L-Carnitine, a compound isolated from meat. In this study, 
100 healthy omnivores and vegan/vegetarians were administered oral L-carnitine to 
comparatively assess plasma and fecal levels of L-carnitine before and after oral antibiotics. 
These levels were examined within several hours of ingestion and again after a two-month 
period of L-carnitine supplementation.  After oral L-carnitine, the omnivore group produced 
greater than 20 times more TMAO compared with vegan/vegetarians (a statically significant 
difference). The presumed route of TMAO formation by gut microbiota was by way of microbial 
transformation of TMA to its newly confirmed intermediary -butyrobetaine (BB). Although 
various gut microbiota are involved in the transformation of TMA from L-carnitine, the 
differences between the groups’ microbiota were not specially detailed, and thus warrant 
further investigation. The CARNIVAL trial is tentatively scheduled to be complete June 2020. 
These preliminary results are limited by small sample size which restricts generalizability. 
Further evaluation with larger sample is necessary to improve external validity. Furthermore, 
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investigations identifying the specific gut microbes involved in TMAO production and other 
possible microbial mechanisms leading to atherogenesis are needed.7 If elevated TMAO levels 
are a risk factor for ASCVD, as suggested in the foregoing evidence, then L-carnitine may 
promote ASCVD risk because of its conversion to TMAO by gut microbiota [see illustration 
below]. Since this amino acid is highly prevalent in meat and in some food supplements, diets 
high in meat or L-carnitine supplements may therefore increase ASCVD risk. 
 
7 Koeth RA, Lam-Galvez BR, Kirsop J, et al. l-Carnitine in omnivorous diets induces an atherogenic gut 
microbial pathway in humans. Journal of Clinical Investigation. 2018;129(1):373-387. doi:10.1172/jci94601. 
 
 
Dietary Influences and Obesity 
 An observational cross-sectional study by Cuesta-Zuluaga et al, examined SCFA levels 
and their association with the gut dysbiosis seen in subjects with obesity and other 
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cardiometabolic risk factors. A relatively large sample of persons was selected throughout 
populations in Colombia and other South American countries. Multiple variables including age, 
gender, diet, physical activity, adiposity (measured by body mass index (BMI), percent body fat, 
and waist circumference), blood chemistries, blood pressure, operational taxonomic unit (OTU) 
richness of gut microbiomes, and fecal SCFAs. Greater fecal butyrate excretion in subjects 
classified as obese was found and was associated with an overall decreased diversity of gut 
microbiota as measured by OTU richness. Inversely, rich variation in gut microbiota diversity 
was associated with the decreased gut permeability seen in subjects with lower BMIs and less 
central abdominal fat. Strengths of this study included its large sample size and its ability to 
control for many confounders including limiting the sample to subjects who did not take any 
medications. A limitation of the study was its design, cross-sectional in contrast to an RCT. The 
measurement of SCFAs in fecal samples only and not serum was another limitation. 
Nonetheless, evidence was found that the microbiome of the obese subjects differs from that 
of the controls, posing the question of why the altered microbiome increases the risk of ASCVD 
in obese persons of mechanistic link. 8 
 
Lipid Regulation and Dyslipidemia 
 Modulation of lipids is a multivariate process and is influenced by many factors, 
including gut microbiome function and composition. The composition of the gut microbiome in 
individuals with ASCVD was successfully characterized by a metagenome-wide association 
study. Specific microbial strains, specific functional modules linked to ASCVD, and enriched 
virulent factors were identified. Of the 218 subjects with known atherosclerotic cardiovascular 
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disease, the richness of Enterobacteriae and Streptococcus spp. was greater than the richness 
of those species in the 187 healthy control subjects. Of the Enterobacteriaceae richness in the 
ASCVD group, specific bacterial genes that encode for lipid synthesis or destruction were found 
and were in contrast to the lower level of Enterobacteriaceae and the otherwise rich 
Bacteroides seen with the control group. Components that contribute to atherogenic plaque 
formation were identified in the bacterial functional gene modules. A greater synthesis of O-
Antigen (a component of lipopolysaccharides) and reduced synthesis of lipid A (the innermost 
component of lipopolysaccharides), was found in high density in the in the Enterobacteriaceae-
associated ASCVD groups.  This finding could explain the link between microbiome composition 
and ASCVD. However, the various drug therapies among subjects may have constituted a 
confounding factor. Further isolation of the disease-associated strains and more in-depth 
knowledge of their functional capacities are necessary before interventions affecting these 
bacteria, and hence ASCVD, can be evaluated. 9  
 In January of this year, Mayo Clinic researchers studied 53 patients with advanced 
coronary artery disease (CAD). Through primary fecal analysis, they identified specific bacteria 
associated with this disease state and compared these results with those from healthy controls. 
An overall decreased gut microbial richness was found in the CAD group compared with the 
matched control group. Specifically, a heavier concentration of Ruminococcus gnavus and a 
decreased concentration of Lachnospiraceae NK4B4 and Ruminococcus gaureauii groups (all are 
of the Firmicutes phylum) were seen in persons with CAD. Limiting factors in this study included 
use of a low phylogenic power of the method of rDNA microbiome analysis, the fact that not all 
CAD patients were identified by angiography, and the small sample size.10 As with many of the 
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aforementioned studies, causal evidence between specific microbes and either cardiovascular 
disease or its risk factors require further substantiation with additional research.   
 In a cross-sectional study of 561 participants, evaluating the interplay between the gut 
microbiome and individual metabolism, 283 subjects with insulin resistance were assessed by 
body composition, lipid profiles, and glucose tolerance in relation to dietary intake. Data was 
gathered by using the semi-quantitative food frequency questionnaire (SQFFQ) to inventory 
particular dietary habits. Stool analysis was performed to identify gut microbiome diversity by 
their OTU and RDP Classifier algorithm. A richness of Bacteroidetes was seen in those subjects 
with lower LDL-C levels and larger amounts of Tenericutes were seen in those with higher total 
cholesterol levels. An abundance of Actinobacteria was found in persons with greater BMIs and 
larger waist and hip circumference. These findings suggested that these specific phyla may have 
played a role in the metabolism of lipids and therefore, alteration in these microbes might have 
contributed to dyslipidemia and metabolic dysfunction. This study was limited by its 
observational design. The use of the subjective SQFFQ tool could have created bias. Further 
investigation is needed to ascertain the exact mechanism of the gut microbiome’s influence on 




 Evidence does indeed indicate that the composition of the gut microbiota in patients 
with ASCVD and known risk factors of obesity and lipid dysregulation compared with those 
without are different. While variation is seen among those persons with ASCVD and known risk 
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factors, the exact cause is still poorly understood. The gut microbiota is influenced by metabolic 
pathways that both downregulate and upregulate synthesis of beneficial and pathogenic 
microbes, respectively. Mechanisms behind these metabolic pathways, including TMAO 
mediated synthesis, warrant further investigation to better understand the involvement in 
atherogenesis. More large-scale metagenome-wide association studies across more diverse 
patient populations could further categorize microbe trends in those persons with ASCVD and 
would provide more insight into what phyla may play a role in the pathogenesis of ASCVD. This 
evidence does not currently provide a basis for pharmacological interventions, but does 
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